A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

Risankizumab

Subcutaneous (SC) Injection

DRUG

Risankizumab

On-Body Injector (OBI)

Trial Locations (4)

Cpmi /Id# 276490, Miami

Acpru /Id# 276043, Grayslake

PPD Phase I Clinic /ID# 276525, Austin

Ppd - Las Vegas Research Unit /ID# 276565, Las Vegas